Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas.

Although having a SMARCB1 or RB1 mutation appeared to be associated with increased odds of having a CDKN2A high meningioma, these did not reach statistical significance and may be confounded by the relative rarity of RB1 mutations in meningiomas (Supplementary Fig. 9c). p16, CDK4 protein abundance corroborates transcriptomic data As the final step in the central dogma, we wanted to determine whether the changes we observed in the gene expression of CDKN2A and CDK4 would also be reflected by their relative protein abundance.

also in 111,027 other papers